Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
02 sept. 2022 06h00 HE
|
Cure Pharmaceutical Holding Corp.
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- CURE...
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman
16 août 2022 06h00 HE
|
Cure Pharmaceutical Holding Corp.
Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years...
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
09 août 2022 09h00 HE
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a...
CURE Pharmaceutical Announces the Appointment of New Board Member
02 août 2022 09h00 HE
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to...
CURE Pharmaceutical Announces Teleconference With Investors
01 août 2022 09h00 HE
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting...
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
28 juil. 2022 09h00 HE
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its...
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
12 mai 2022 13h42 HE
|
Cure Pharmaceutical Holding Corp.
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated...
Sera Labs Inc. Products Now Available at Walmart, Bed Bath & Beyond, CVS and Target.com
14 avr. 2022 08h00 HE
|
Cure Pharmaceutical Holding Corp.
LOS ANGELES, April 14, 2022 (GLOBE NEWSWIRE) -- Sera Labs, a wholly subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), today announced its Seratopical Revolution skincare line will be sold...
CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico
03 mars 2022 11h18 HE
|
CURE Pharmaceutical Holding Corp.
OXNARD, Calif. and LAS VEGAS, March 03, 2022 (GLOBE NEWSWIRE) -- Cure Pharmaceutical (OTC: CURR) a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness...
Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor
09 déc. 2021 07h30 HE
|
CURE Pharmaceutical Holding Corp.
LOS ANGELES and TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- The Sera Labs, a wholly owned subsidiary of CURE Pharmaceutical Holdings (OTCQB: CURR) today announced its global expansion into Canada by...